Voyager Therapeutics, Inc.
VYGR
$3.26
-$0.15-4.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.47M | -27.94M | -27.43M | -27.89M | -33.38M |
| Total Depreciation and Amortization | 908.00K | 932.00K | 1.05M | 932.00K | 1.07M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.59M | 3.39M | 4.32M | 4.04M | 4.55M |
| Change in Net Operating Assets | -5.87M | -9.81M | -8.20M | -8.13M | -5.49M |
| Cash from Operations | -25.84M | -33.42M | -30.26M | -31.05M | -33.26M |
| Capital Expenditure | 0.00 | -14.00K | -626.00K | -207.00K | -1.11M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.39M | 8.12M | 48.05M | 35.10M | 3.04M |
| Cash from Investing | 15.39M | 8.10M | 47.42M | 34.89M | 1.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.91M | 3.33M | 136.00K | 85.00K | 513.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.91M | 3.33M | 136.00K | 85.00K | 513.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.55M | -21.99M | 17.30M | 3.93M | -30.82M |